OneSource Specialty Pharma Limited reported a significant turnaround in Q4 FY26, with revenue reaching US$48 million, a 47% sequential increase. EBITDA also saw a sharp recovery, expanding by 1,550 basis points quarter-over-quarter. Driven by the commercial launch of generic Semaglutide in India and key approvals in the US and Canada, the company reaffirmed its long-term FY28 guidance of US$400 million in organic revenue and 40% EBITDA margins.
Quarterly Financial Performance
The company demonstrated a robust recovery during the quarter ended March 31, 2026. Revenues stood at INR 4,282 million, reflecting a 47% sequential growth compared to the previous quarter. This growth was fueled by broad-based performance across service offerings and the commercial launch of Semaglutide. Profitability also improved substantially, with the Q4 EBITDA reported at INR 919 million, which is more than 5x higher than the previous quarter.
Strategic Milestones and Capacity Expansion
OneSource has achieved critical regulatory milestones, including multiple approvals for Semaglutide in Canada and US markets. The company is actively expanding its manufacturing capabilities to meet rising global demand. A new production line, part of a US$ 100 million capex program, is currently undergoing qualification and is expected to be available for commercialization in Q2. By the end of the year, the company expects to have three lines installed, significantly increasing its capacity for finished, packed product assembly.
Business Outlook and Strategic Focus
Management confirmed that the company has decided to defer the previously announced scheme of arrangement regarding the Steriscience and Brooks assets. This decision follows feedback from smaller investors regarding valuation and recent market pricing volatility. Going forward, the company remains singularly focused on its core FY28 growth trajectory. Additionally, the biologics business is showing strong momentum, with the project funnel expanding 4x over the past year, securing new partnerships with major European and US biosimilar firms.
Source: BSE
